Bayer Shareholders Keep the Squeeze on CEO Over Roundup Saga (1)

As Bayer AGtries to draw a line under costly Roundup herbicide litigation in the US this year, shareholders made clear at its annual general meeting that the stakes are higher than ever — including for Chief Executive Officer Bill Anderson.

Anderson told investors Friday that the company has made “great progress” over the past two years, pointing to a stronger drug pipeline and advances in efforts to contain the legal fallout from its $63 billion Monsanto acquisition in 2018. But he also cautioned that “the work isn’t complete. Yet.”

Bill Anderson at the Hanover trade fair, on Monday, April 20, 2026.

Photographer: Krisztian Bocsi/Bloomberg

“This remains an active situation, with important milestones ...